Search
Nisoldipine
go.drugbank.com/drugs/DB00401ApprovedNisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in s...
Categories: Antihypertensive Agents Indicated for HypertensionMetolazone
go.drugbank.com/drugs/DB00524ApprovedInvestigationalA quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
Categories: Antihypertensive Agents Indicated for HypertensionVLTS-934
go.drugbank.com/drugs/DB05597InvestigationalVLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).
PF-04457845
go.drugbank.com/drugs/DB12012InvestigationalPF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.
Gemigliptin
go.drugbank.com/drugs/DB12412InvestigationalGemigliptin has been investigated for the treatment of Cancer and Cisplatin Adverse Reaction.
TG-1042
go.drugbank.com/drugs/DB18435InvestigationalTG-1042 (formerly known as ASN-002) is a recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene.
Beinaglutide
go.drugbank.com/drugs/DB15072InvestigationalBeinaglutide is under investigation in clinical trial NCT03829891 (Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus).
Citarinostat
go.drugbank.com/drugs/DB15449InvestigationalCitarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).
Olaparib-bodipy FL
go.drugbank.com/drugs/DB16263InvestigationalOlaparib-bodipy FL is under investigation in clinical trial NCT03085147 (A Dye for the Detection of Cancer of the Tongue and Mouth).
Pyrrolizidine
go.drugbank.com/drugs/DB19159InvestigationalPyrrolizidine is under investigation in clinical trial NCT05898373 (Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC).